Want to see JP:4539 full AI Analyst Report?

Nippon Chemiphar Co., Ltd. (4539) Price & Analysis

1 Followers

4539 Stock Chart & Stats

¥1585.00

-¥7.00(-0.46%)

At close: Jan 08 4:00 PM EST

¥1585.00

-¥7.00(-0.46%)

Day’s Range― - ―

52-Week Range¥1,504.00 - ¥1,857.00

Previous CloseN/A

Volume500.00

Average Volume (3M)1.88K

Market Cap

¥5.59B

Enterprise Value¥17.12B

Total Cash (Recent Filing)¥9.69B

Total Debt (Recent Filing)¥19.02B

Price to Earnings (P/E)―

Beta0.18

Next Earnings

Oct 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.26%

Share Statistics

EPS (TTM)109.50

Shares Outstanding4,261,420

10 Day Avg. Volume1,810

30 Day Avg. Volume1,880

Financial Highlights & Ratios

PEG Ratio-0.99

Price to Book (P/B)0.33

Price to Sales (P/S)0.19

P/FCF Ratio-27.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue RecoveryThe sharp revenue recovery indicates renewed demand and improved commercial traction after the prior-year decline. If the rebound persists, a larger sales base can support operating leverage, broader product reach, and more resources for maintaining the company’s prescription-drug franchise.

Balance Sheet StabilityA relatively stable asset and equity base, combined with moderate leverage and lower debt in 2026, provides financial resilience for a specialty and generic pharmaceutical business. This structure should preserve capacity to fund operations and manage business volatility over the next several quarters.

Recurring Prescription PortfolioThe domestic prescription-drug model provides recurring access to hospitals, clinics, pharmacies, wholesalers, and distributors. Generic and off-patent products can support durable revenue through established medicines, multiple dosage forms, regulatory approvals, availability, and stable supply.

Bears Say

Weak Cash GenerationRepeated free-cash-flow deficits reduce confidence that reported earnings consistently convert into funding for the business. Volatile operating cash flow can constrain investment, debt reduction, and shareholder distributions, leaving less flexibility if operating conditions weaken.

Thin, Volatile ProfitabilityThe return to profitability is encouraging, but the recent pattern remains inconsistent and earnings are still below the stronger 2022 level. Thin and volatile profits provide a limited buffer against changes in product mix, pricing, or operating costs and weaken earnings visibility.

Low Return On EquityLow and uneven returns on equity indicate that the company is generating limited earnings relative to its capital base. Even with a reasonably stable balance sheet, subdued capital productivity can restrict internally funded growth and make sustained improvement in shareholder returns more difficult.

4539 FAQ

What was Nippon Chemiphar Co., Ltd.’s price range in the past 12 months?

Nippon Chemiphar Co., Ltd. lowest stock price was ¥1504.00 and its highest was ¥1857.00 in the past 12 months.

What is Nippon Chemiphar Co., Ltd.’s market cap?

Nippon Chemiphar Co., Ltd.’s market cap is ¥5.59B.

When is Nippon Chemiphar Co., Ltd.’s upcoming earnings report date?

Nippon Chemiphar Co., Ltd.’s upcoming earnings report date is Oct 30, 2026 which is in 6 days.

How were Nippon Chemiphar Co., Ltd.’s earnings last quarter?

Nippon Chemiphar Co., Ltd. released its earnings results on Jul 31, 2026. The company reported -¥26.46 earnings per share for the quarter.

Is Nippon Chemiphar Co., Ltd. overvalued?

According to Wall Street analysts Nippon Chemiphar Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nippon Chemiphar Co., Ltd. pay dividends?

Nippon Chemiphar Co., Ltd. pays a Annually dividend of ¥50 which represents an annual dividend yield of 3.26%. See more information on Nippon Chemiphar Co., Ltd. dividends here

What is Nippon Chemiphar Co., Ltd.’s EPS estimate?

Nippon Chemiphar Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nippon Chemiphar Co., Ltd. have?

Nippon Chemiphar Co., Ltd. has 4,261,420 shares outstanding.

What happened to Nippon Chemiphar Co., Ltd.’s price movement after its last earnings report?

Nippon Chemiphar Co., Ltd. reported an EPS of -¥26.46 in its last earnings report. Following the earnings report the stock price went up 2.532%.

Which hedge fund is a major shareholder of Nippon Chemiphar Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4539

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nippon Chemiphar Co., Ltd.

Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a global pharmaceutical entity engaged in the research, production, marketing, and sale of ethical drugs and diagnostic agents. Its diagnostic product lineup features the IgE NC kit, which measures overall IgE levels and identifies 57 specific allergens, as well as the DP3000 device for accurate allergen-specific IgE testing. The company's development pipeline includes NC-2400, a PPAR-delta agonist; NC-2500, a novel xanthine oxidoreductase inhibitor targeting hyperuricemia and gout; and NC-2600, a P2X4 receptor antagonist for neuropathic pain. Additionally, it is advancing NC-2700, a new urate transporter 1 inhibitor designed to enhance urinary urate excretion, and NC-2800, a delta opioid receptor agonist for treating depression and anxiety. Its commercialized pharmaceuticals comprise Uralyt-U (an alkalization therapeutic), Soleton (an analgesic and anti-inflammatory medication), and Calvan (a drug for hypertension). Beyond pharmaceuticals, Nippon Chemiphar offers a variety of quasi-drugs, nutritional supplements, health foods, cosmetics, and different types of creams. Its generic medications reach hospitals and pharmacies via wholesale distributors. Founded in Tokyo, Japan, in 1950, the company was initially known as Hitachi Chemical Co., Ltd., changing its name to Nippon Chemiphar Co., Ltd. in 1970.